Mr. Bender has over 25 years of biopharmaceutical leadership experience and has helped take products leveraging novel drug delivery techniques from discovery through Phase III development. Prior to founding Intensity Therapeutics, Mr. Bender was the CEO of Interleukin Genetics, a personalized medicine company, from January 2008 until August 2012. At Interleukin, Mr. Bender successfully restructured the Company, increased sales eight-fold, developed a new genetic-based testing platform and partnered with a large insurance provider to initiate studies leading to reimbursement of the Company’s lead product. Prior to joining Interleukin, Mr. Bender held numerous positions at Emisphere Technologies, Inc., a drug delivery company specializing in the oral delivery of poorly absorbed molecules, , including: Interim President & CEO, Chief Technology Officer, Senior Vice President of Business Development, and Vice President of Manufacturing and Process Development.
During his career, Mr. Bender has partnered with several major pharmaceutical and biotech companies using structures such as joint ventures, licensing and research collaboration agreements. In addition, Mr. Bender has been successful in raising (or helping to raise) capital with institutional investors using several vehicles such as registered direct placements, PIPES, S-3 & S-1 filings, and convertible debt. He has raised approximately $20 million in capital for Intensity Therapeutics with multiple types of investors.
Mr. Bender has a S.B. and S.M. in Chemical Engineering from the Massachusetts Institute of Technology (MIT), an MBA from the Wharton School of the University of Pennsylvania (Penn) and an MA in International Studies from Penn. He spent several years living in Switzerland and speaks French, German and Swiss-German dialect.